Abstract
Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels
| Original language | English |
|---|---|
| Pages (from-to) | 459-468 |
| Number of pages | 10 |
| Journal | The oncologist |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2004 |
Fingerprint
Keywords
- Anemia
- Cancer
- Epoetin alfa
- Hemoglobin
- Induction therapy
ASJC Scopus subject areas
- Cancer Research
- Hematology
Cite this
Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy. / Cortesi, Enrico; Mancuso, Andrea; De Pasquale Ceratti, Adolfo; Pizzardi, Nicolina; D'Auria, Giuliana; Accettura, Caterina; Beccaglia, Patrizia; Bertelletti, Daniela; De Marinis, Filippo.
In: The oncologist, Vol. 9, No. 4, 2004, p. 459-468.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy
AU - Cortesi, Enrico
AU - Mancuso, Andrea
AU - De Pasquale Ceratti, Adolfo
AU - Pizzardi, Nicolina
AU - D'Auria, Giuliana
AU - Accettura, Caterina
AU - Beccaglia, Patrizia
AU - Bertelletti, Daniela
AU - De Marinis, Filippo
PY - 2004
Y1 - 2004
N2 - Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels
AB - Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels
KW - Anemia
KW - Cancer
KW - Epoetin alfa
KW - Hemoglobin
KW - Induction therapy
UR - http://www.scopus.com/inward/record.url?scp=3543024463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3543024463&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.9-4-459
DO - 10.1634/theoncologist.9-4-459
M3 - Article
C2 - 15266099
AN - SCOPUS:3543024463
VL - 9
SP - 459
EP - 468
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 4
ER -